CAVA's 34% Crash Sets Up Binary Earnings Bet
CAVA Group reports Q2 2026 after the close tonight. Options price an 11% swing on a stock already down 34% from highs. Here's what traders need to know.
Key Points
- CAVA enters tonight's Q2 print at roughly $64, down 34% from its 52-week high of $98.79, with the options market pricing an 11% move in either direction on the report.
- A sector-wide selloff tied to an FDA cyclosporiasis outbreak — centered on Sweetgreen, not CAVA — has done most of the damage, creating a potential overreaction setup if tonight's fundamentals hold.
- The critical trigger is not the EPS line but whether management raises the full-year comp guide a second time and whether traffic, not menu price, is still doing the growth lifting.
CAVA Group reports Q2 2026 earnings after the close tonight at 4:10 PM ET, with the analyst call at 5:00 PM ET. The Zacks consensus calls for $0.17 in EPS — up 6.3% year-over-year — on revenue of $353.3 million, implying 25.9% top-line growth. The options market is pricing an 11% swing either way on a stock that has already been cut nearly in half from its highs. That asymmetry is what makes tonight the most consequential restaurant print of the quarter.
The Damage That Wasn't CAVA's Fault
The 34% slide from CAVA's 52-week high of $98.79 to the current $64 handle is not primarily a CAVA story — it is a sector contagion story. An FDA cyclosporiasis outbreak hit the fast-casual restaurant space this summer, with Sweetgreen absorbing the sharpest operational blow. CAVA has not been directly implicated, but the sector selloff was indiscriminate. Investors who price restaurant stocks on a portfolio basis rotated out broadly, and CAVA — trading at a premium multiple north of 120x earnings — offered no valuation cushion to absorb the fear.
That backdrop matters because it sets up a potential mean-reversion trade if CAVA's underlying business shows no sign of traffic damage in tonight's print. The analyst community has not abandoned the name. Morgan Stanley upgraded to Overweight on July 15 with a $90 target, explicitly acknowledging the premium multiple and calling the stock worth owning regardless. Telsey has an Outperform with a $95 target and describes the company's growth targets as "conservative." RBC Capital's $90 Outperform note specifically flags the recent price weakness as an opportunity. The mean analyst target sits at $91.29 — 42.6% above the current print. That is not a community that sees a broken story. It is a community waiting for the noise to clear.
The more cautious voice is Citi, which trimmed its target to $79 ahead of the print in what reads as a pre-earnings de-risk rather than a fundamental reassessment. Citi's move is the kind of target cut designed to protect a rating, not signal a thesis change. That distinction matters when reading the analyst tape going into tonight.
What the Print Actually Needs to Show
At 120x earnings, CAVA does not get credit for meeting the number — it gets punished for falling short of the narrative. The headline EPS of $0.17 and the $353.3 million revenue figure are table stakes. The last four quarters show an average earnings surprise of 16.6%, with three beats in four attempts. The most recent quarter beat the Zacks consensus by 17.7%. The street is aware of the beat history and has baked in at least some probability of another upside surprise. A clean beat that lands in line with elevated whisper numbers moves the stock modestly. A miss — even a small one — given the current multiple, sends it materially lower.
The real number to watch is same-restaurant sales composition. Management flagged heading into Q2 that comp trends were tracking above the raised full-year outlook. If that holds through the June 30 quarter-end and traffic is still the primary driver — not check inflation from menu price increases — it validates the unit economics story that justifies the premium. CAVA's investment case is built on the proposition that it can compound traffic growth the way Chipotle did in its adolescent phase, while keeping food costs and labor ratios in check. Any sign that menu price is now doing the heavy lifting signals a maturing growth curve, and the multiple compression that follows would be severe.
Full-year 2026 revenue estimates have already been revised up to $1.498 billion from $1.458 billion over the past 90 days. Full-year EPS estimates have moved from $0.53 to $0.56 over the same window. Both revisions reflect genuine earnings momentum, and management has already raised the full-year comp guide once. A second raise tonight — explicit or embedded in the tone of guidance — is the single most bullish outcome available. It would signal that Q2's above-trend comp performance was not a one-quarter event and that the Mediterranean category is still taking share from the broader fast-casual complex, outbreak noise included.
What Traders Watch Next
Position sizing into a binary print on a 120x multiple stock is a risk management decision as much as a fundamental one. The 11% implied move priced by options represents the market's best estimate of the earnings-day range — roughly $57 to $71 bracketing the current $64 level. The downside scenario, a miss or a flat guide, takes CAVA toward the $57 area, which would represent a 42% decline from the 52-week high and begin to approach levels where the valuation argument becomes genuinely compelling on a two-year forward basis. The upside scenario on a strong beat with a raised guide targets a retest of the $72 to $75 range, which is where the stock was trading before the cyclosporiasis outbreak headlines began landing in late June.
For traders holding through the print, the analyst call at 5:00 PM ET is where the real information lives. Management's specific language around traffic trends, new unit development, and the cadence of the full-year comp trajectory will move the stock more than the reported numbers. Check tonight's earnings release timing and call details at Yahoo Finance. The sector macro is also not fully resolved — the FDA outbreak investigation remains open, and any incremental update that broadens the scope to include CAVA's supply chain would reset the entire thesis regardless of tonight's headline numbers. Watch that channel in parallel. The cleaner setup for non-binary-event traders is to wait for the print, assess the comp guide language on the call, and position for the re-rate trade in the days following if the numbers confirm the analyst bull case — targeting the $91 mean analyst price over a three-to-six-month horizon against a defined stop below the $57 post-earnings support level.
The Weekly Investor
Daily market analysis for active traders. Free.
